Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Treatment of LNCaP prostate cancer cells with EGF and NRG

ABSTRACT: Treatment of LNCaP prostate cancer cells with EGF and NRG

PROVIDER: PRJNA1289199 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Treatment of LNCaP prostate cancer cells with EGF and NRG

Project description:Gene expression signatures are routinely used to infer pathway activity. In this project, we stimulated LNCaP prostate cancer cells with growth factors to derive gene expression sigantures indicative of pathway activation.

2025-08-21 | GSE302203 | GEO

LNCaP prostate cancer cells

Project description:LNCaP prostate cancer cells

| PRJNA801659 | ENA

RNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide

Project description:LNCaP prostate cancer cells were stimulated with the synthetic androgen R1881. RNA-sequencing was performed to identify changes induced by darolutamide treatment on the transcriptome level.

2025-01-02 | GSE280187 | GEO

RNA-sequencing of LNCaP prostate cancer cells with and without treatment of enzalutamide

Project description:LNCaP prostate cancer cells were stimulated with the synthetic androgen R1881. RNA-sequencing was performed to identify changes induced by enzalutamide treatment on the transcriptome level.

2023-02-15 | GSE220097 | GEO

50uM Casodex treatment of LNCaP Prostate Cancer cells

Project description:Genome wide expression changes following 50uM Casodex treatment were investigated to determine regulatory targets commonly overlooked in gene function specific microarrays and for comparison of the effects of the mutant androgen receptor (AR) LNCaP cell line against the wild-type AR expressing PC-346C cells. LNCaP Prostate Cancer cells were treated for a period of 48h with or without 50uM Casodex following a 24h seeding period. At the selected time point, total RNA was harvested from the cells for hybridization and analysis by Nimblgen Systems Inc using the homo sapiens gene expression array.

2007-09-15 | E-GEOD-8533 | biostudies-arrayexpress

Microarray Analysis of DU 145, LNCaP and PC-3 Prostate Cancer Cell Lines upon Docetaxel treatment

Project description:We measured the effect of docetaxel treatment to three differentially responsive prostate cancer cell lines, LNCaP, DU145 and PC-3, based on a transcriptional time course response by microarray analysis. These cell lines represent both androgen independent (DU145 and PC-3) and androgen sensitive (LNCaP) cells

2016-07-21 | GSE83654 | GEO

R1881 treatment modulates LNCaP proteome.

Project description:The androgen receptor is considered as the key promoter of prostate cancer. It is a transcription factor that controls the transcription of hundreds of its target genes. In this project we focuses on how androgen receptor stimulation by the synthetic androgen R1881 can affect the proteome of peroxiosmes and the antioxidant enzymes in LNCaP cells.

2024-11-01 | PXD054374 | Pride

Siomycin A treatment in prostate cancer cell lines PC3 and LNCaP

Project description:Siomycin A treatment in prostate cancer cell lines resulted in a concurrent inhibition of specific cell cycle genes and strongly impaired cell viability. Illumina microarray experiments were done using PC3 and LNCaP cell lines treated with 0.5 microM Siomaycin A either 24h or 48h in triplicates.

2012-10-19 | E-GEOD-36531 | biostudies-arrayexpress

miR-NC or miR-331-3p treatment of LNCaP prostate cancer cells

Project description:LNCaP prostate cancer cells were treated for 24 hours with either a miRNA negative control (miR-NC) or miRNA 331-3p (miR-331-3p)

2017-03-23 | GSE96918 | GEO

Effects of Cardiac Glycosides on RNA Expression in Prostate Cancer LNCaP-abl Cells

Project description:Prostate cancer is the most common cancer in men and cardiac glycosides inhibit prostate cancer cell proliferation. In order to investigate the mechanism by which cardiac glycosides inhibit prostate cancer cells, we observed genome-wide RNA expression in prostate cancer LNCaP-abl cells, hormone resistant cells, after the cardiac glycoside treatment using RNA-Seq. In addition, we profiled LNCaP-abl cells after androgen receptor (AR) knockdown to observe whether cardiac glycoside effect on RNA expression is similar to that of AR knockdown.

2012-04-04 | GSE35126 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data